Detection of cardiac calcinosis in hemodialysis patients by whole-body scintigraphy with 99m-technetium methylene diphosphonate

American Journal of Nephrology

Volumn 20, Issue 4, 2000, Pages 278-282

  Eguchi, Mariko ^a   Tsuchihashi, Kazufumi ^a   Takizawa, Hideki ^a   Nakahara, Narifumi ^a   Hagiwara, Makoto ^a   Ohnishi, Hirofumi ^a   Torii, Taka Aki ^a   Hashimoto, Akiyoshi ^a   Marusaki, Shigeru ^b   Nakata, Tomoaki ^a   Ura, Nobuyuki ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Obihiro Kyohkai Hospital   (Japan)

Author keywords

99m Technetium methylene diphosphate; Cardiac calcinosis; Cardiomyopathy; Hemodialysis; Mitral annular calcinosis; Secondary hypoparathyroidism

Indexed keywords

MEDRONATE TECHNETIUM TC 99M; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CALCIFICATION; CALCINOSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; KIDNEY FAILURE; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; WHOLE BODY SCINTISCANNING;

EID: 0033824054     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000013601     Document Type: Article

References (11)

1. DePace NL, Rohrer AH, Kotler MN, Brezin JM, Parry WR: Rapidly progressing, massive mitral annular calcification. Occurrence in a patient with chronic renal failure. Arch Intern Med 1981;141:1663-1665.
2. Rostand SG, Sanders C, Kirk SG, Rutsky EA, Fraser RG: Myocardial calcification and cardiac dysfunction in chronic heart failure. Am J Med 1988;85:651-657.
3. Nagao K, Tsuchihashi K, Ura N, Nakata T, Shimamoto K: Appropriate hematocrit levels of erythropoietin supplement therapy in end-staged renal failure complicated by coronary artery disease. Can J Cardiol 1997;13:747-753.
4. Kudoh Y, Iimura O: Study on the atherosclerosis mechanism in chronic hemodialysis. Jpn Circ J 1987;51:631-641.
5. Takizawa H, Ura N, Yonekura S, Yoshida S, Watarai I, Shimamoto K: Evaluation of atherosclerosis in hemodialysis patients: Comparison between carotid arteriography and abnormal aortography on CT. J Jpn Soc Dial Ther 1998; 31:1431-1435.
6. Tsuchihashi K, Nozawa A, Marusaki S, Ohnuma Y, Kuno A, Takagi S, Takizawa H, Ura N, Shimamoto K: Mobile intracardiac calcinosis: A new risk of thrombo-embolism in patient with hemodialysed endstaged renal disease. Heart 1999;82:638-640.
7. Katz AI, Hampers CL, Merrill JP: Secondary hyperparathyroidism and renal osteodystrophy in chronic renal failure. Analysis of 195 patients, with observations on the effect of chronic dialysis, kidney transplantation and subtotal parathyroidectomy. Medicine 1969; 48:337-374.
8. Hampers CL, Katz AI, Wilson RE, Merrill JP: Calcium metabolism and osteodystrophy after renal transplantation. Arch Intern Med 1969; 124:282-291.
9. Tsuchihashi K, Takizawa H, Torii T, Ikeda R, Nakahara N, Yuda S, Kobayashi N, Nakata T, Ura N, Shimamoto K: Hypoparathyroidism potentiates cardiovascular complication through disturbed calcium metabolism: Possible risk of vitamin D3 analog administration in dialysis patients with end-stage renal disease. Nephron 2000;84:13-20.
10. Fernandez E, Montoliu J: Successful treatment of massive uremic tumoral calcinosis with daily haemodialysis and very low calcium dialysate. Nephrol Dial Transplant 1994;9:1207-1209.
11. Ueyoshi A, Ota K: Clinical appraisal of vinpocetine for the removal of intractable tumoral calcinosis in hemodialysis patients with renal failure. J Int Med Res 1992;20:435-443.